- Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy. [Review]Prostate. 2026 Aug 02. [Online ahead of print]P
- CONCLUSIONS: Hormonal agents such as cyproterone acetate and estrogen appear to be the most effective treatments, although they are associated with side effects. Non-pharmacological options like acupuncture and CBT may offer some benefit, while dietary supplements seem to be ineffective. Future studies are needed also to evaluate newer treatments, such as fezolinetant, in this patient population.
- Publisher Full Text (DOI)
- Comparisons of Novel Risk Stratification Models to the Current cT1a/b Staging in Incidental Prostate Cancer. [Journal Article]Prostate. 2026 Aug 02. [Online ahead of print]P
- CONCLUSIONS: Of all tested stratification models, the consideration of GS stratified between < 8 and ≥ 8 resulted in the best survival discrimination, as well as highest accuracy after cross-validation. In consequence, the use of this model (GS < 8 vs. ≥ 8) appears better suited than the standard cT1a vs. cT1b substaging, when CSS represents the endpoint of interest.
- Publisher Full Text (DOI)
- Clinical Impact of Gleason Pattern 5 on Doublet Versus Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer. [Journal Article]Prostate. 2026 Aug 02. [Online ahead of print]P
- CONCLUSIONS: Triplet therapy was associated with longer CRPC-FS than apalutamide- or enzalutamide-based doublet therapy in systemic treatment-naïve mHSPC. This association appeared more evident in patients with GP5-positive disease. Given the shorter follow-up in the triplet group, limited event numbers in subgroup and PFS2 analyses, and the nonrandomized nature of post-CRPC treatment sequencing, these findings should be interpreted as hypothesis-generating.
- Publisher Full Text (DOI)
- Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era. [Review]Prostate. 2026 Aug 02. [Online ahead of print]P
- CONCLUSIONS: PSMA-PET is a practice-changing staging modality in N1M0 prostate cancer, but whether earlier detection and treatment escalation translate into meaningful survival benefit remains uncertain.
- Publisher Full Text (DOI)
- Predictive Value of [-2]proPSA-Related Indices for Prostate Cancer Detection Years Before Prostate-Specific Antigen Elevation: Insights From a Five-Year Longitudinal Screening Cohort. [Journal Article]Prostate. 2026 Aug 02. [Online ahead of print]P
- CONCLUSIONS: p2PSA-related indices showed group-level differences between future PC cases and matched controls before PSA exceeded conventional cut-offs. These findings should be regarded as hypothesis-generating and require validation in prospective studies before clinical application to risk-stratified screening.
- Publisher Full Text (DOI)
- Evaluation of [[225]Ac]Ac-PSMA-617 vis-a-vis Rechallenge [[177]Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario. [Journal Article]Prostate. 2026 Jul 26. [Online ahead of print]P
- CONCLUSIONS: Postdocetaxel mCRPC patients with progressive disease following initial course of [[177]Lu]Lu-PSMA-617 when treated with [[225]Ac]Ac-PSMA-617PRLT showed favorable and encouraging clinical, biochemical, and imaging response rates along with longer PFS and OS with minimal treatment-related toxicities. Rechallenge [[177]Lu]Lu-PSMA-617 and chemotherapy-based approaches also provided clinical benefit in selected patients, reflecting the range of salvage treatment strategies employed in real-world practice. Future large-sized, prospective randomized trials are needed to establish the efficacy of all these treatments particularly alpha-based PRLT in clinical practice of mCRPC patients.
- Publisher Full Text (DOI)
- Intense Focal Peripheral Uptake Pattern on 18F-PET/PSMA as a Predictor of Histological Upgrading in Prostate Cancer. [Journal Article]Prostate. 2026 Jul 23. [Online ahead of print]P
- CONCLUSIONS: The presence of IFPUP on PET/PSMA is an independent predictor of histologic upgrading in localized prostate cancer. Its high specificity and positive predictive value suggest clinical utility as a complementary preoperative biomarker for risk stratification, warranting validation in larger cohorts.
- Publisher Full Text (DOI)
- Prognostic Significance of the Modified Glasgow Prognostic Score and Systemic Immune-Inflammation Index in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Cabazitaxel. [Journal Article]Prostate. 2026 Jul 19. [Online ahead of print]P
- CONCLUSIONS: mGPS and SII are significant prognostic biomarkers in patients with mCRPC treated with CBZ. Their combined assessment may provide improved risk stratification and support clinical decision-making in this population group.
- Publisher Full Text (DOI)
- Evaluating Risk Factors Associating With Late Recurrence After Low-Dose-Rate Brachytherapy for Prostate Cancer Using Machine Learning. [Journal Article]Prostate. 2026 Jul 16. [Online ahead of print]P
- CONCLUSIONS: PSA level and PSA-DT at 5 years were strong predictors of late BCR after LDR-BT. These findings suggest that follow-up intervals may be safely extended for low-risk patients, thereby reducing the burden of hospital visits and healthcare costs.
- Publisher Full Text (DOI)
- A Triple Clinical Filter Model for Selective Omission of Systematic Cores in Transperineal Cognitive Prostate Biopsy: A Retrospective Observational Study. [Journal Article]Prostate. 2026 Jul 16. [Online ahead of print]P
- CONCLUSIONS: In carefully selected patients with elevated PSA density, larger mpMRI visible lesions, and high PI-RADS scores, transperineal cognitive MRI-targeted biopsy may support the selective omission of systematic cores without compromising diagnostic reliability. In contrast, systematic sampling remains indispensable in lower-risk profiles, underscoring the value of a risk-adapted biopsy strategy.
- Publisher Full Text (DOI)
- Years of Life Lost in Incidental Prostate Cancer. [Journal Article]Prostate. 2026 Jul 08. [Online ahead of print]P
- CONCLUSIONS: IPCa patients with advanced Gleason sum or clinical stage exhibited substantial YLL disadvantages, when they did not benefit from active treatment. Therefore, these patients should receive active treatment. Conversely, omitting active treatment in low-risk IPCa patients did not impact premature death.
- Publisher Full Text (DOI)
- Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer. [Journal Article]Prostate. 2026 Jul 02. [Online ahead of print]P
- CONCLUSIONS: Omission of initial ADT during RT is associated with an increased risk of salvage ADT in unfavorable intermediate-risk and high-risk prostate cancer. These real-world, population-based estimates help inform patient counseling and facilitate personalized treatment decisions.
- Publisher Full Text (DOI)
- A Simple Cell Culture Assay for Human Prostatic Branching Morphogenesis Spotlights Bone Morphogenetic Protein Signaling as a Therapeutic Target in Benign Prostatic Hyperplasia. [Journal Article]Prostate. 2026 Jul 02. [Online ahead of print]P
- CONCLUSIONS: We have described a straightforward cell culture assay for human prostatic budding/branching morphogenesis that in particular spotlights IGFs and BMPs as candidate therapeutic targets in BPH. Additional preclinical testing is warranted.
- Publisher Full Text (DOI)
- Temporal Trends of Metastatic Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era in the United States. [Journal Article]
- CONCLUSIONS: The introduction of PSMA PET resulted in an increase in the proportion of mPCa patients in the United States. Within those, M1a and M1b substages increased, but M1c decreased. These observations suggest a stage migration phenomenon, where low burden mPCa (M1a and M1b) is diagnosed more frequently at the expense of high burden mPCa (M1c).
- Publisher Full Text (DOI)
- Holmium Laser Enucleation of the Prostate (HoLEP) With Proactive Preservation of One Lateral Lobe: A Technique for Benign Prostatic Hyperplasia to Preserve Sexual Function. [Journal Article]Prostate. 2026 Jul 02. [Online ahead of print]P
- CONCLUSIONS: For patients who satisfy the inclusion and exclusion criteria, PLL-HoLEP can reduce the incidence of transient urinary incontinence and retrograde ejaculation and more effectively preserve the sexual function of patients with BPH.
- Publisher Full Text (DOI)